APA: Ketamine Noninferior to ECT for Treatment-Resistant Depression

31 May 2023
www.drugs.com
Clinical ResultPhase 3
WEDNESDAY, May 31, 2023 -- For patients with treatment-resistant major depression without psychosis, ketamine is noninferior to electroconvulsive therapy (ECT), according to a study published online May 24 in the New England Journal of Medicine to coincide with the annual meeting of the American Psychiatric Association, held from May 20 to 24 in San Francisco.
Amit Anand, M.D., from Brigham and Women's Hospital in Boston, and colleagues conducted an open-label, randomized, noninferiority trial involving patients referred to ECT clinics for treatment-resistant major depression without psychosis. Participants were recruited and randomly assigned to receive ketamine or ECT (200 and 203 individuals, respectively); patients received ECT three times per week or ketamine twice per week during an initial three-week treatment phase. Ketamine was administered to 195 patients and ECT to 170.
The researchers found that 55.4 and 41.2 percent of patients in the ketamine and ECT groups, respectively, had a response to treatment (decrease of ≥50 percent from baseline in the score on the 16-item Quick Inventory of Depressive Symptomatology-Self-Report; difference, 14.2 percentage points; P
"People with treatment-resistant depression suffer a great deal, so it is exciting that studies like this are adding new options for them," Anand said in a statement. "With this real-world trial, the results are immediately transferable to the clinical setting."
Several authors disclosed ties to the biopharmaceutical industry.
Abstract/Full Text (subscription or payment may be required)
Editorial (subscription or payment may be required)
More Information
Posted May 2023
For more details,please visit the original website
The content of the article does not represent any opinions of Synapse and its affiliated companies. If there is any copyright infringement or error, please contact us, and we will deal with it within 24 hours.
Organizations
Indications
Targets
-
Drugs
Chat with Hiro
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.